NCT05277623View on ClinicalTrials.gov

Effect of Mannitol on Postreperfusion Syndrome During Living Donor Liver Transplant

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 4, 2022

Primary Completion Date

November 5, 2022

Study Completion Date

December 10, 2022

Conditions
Liver Transplant Disorder
Interventions
DRUG

Mannitol

During the anhepatic phase, the patients in the mannitol group (30) will receive 1 g/kg

OTHER

0.9% normal saline

the same amount of 0.9% normal saline

Trial Locations (1)

Unknown

Medicine Ain Shams University, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER